Individual-level, Network-level and City-level Factors Associated with HIV Prevalence Among People Who Inject Drugs in Eight Russian Cities: a Cross-sectional Study
Overview
Authors
Affiliations
Objectives: To ascertain HIV prevalence among people who inject drug (injection drug users (IDUs)) in the Russian Federation and identify explanations for the disparity in different cities.
Design: Cross-sectional survey with serological testing for HIV and hepatitis C virus prevalent infections.
Setting: 8 Russian cities-Irkutsk, Omsk, Chelyabinsk, Yekaterinburg, Naberezhnye Chelny, Voronezh, Orel and St Petersburg.
Participants: In 2007-2009 active IDUs were recruited by respondent-driven sampling with a target sample size of 300 or more in each city.
Main Outcome Measures: Participants were administered a questionnaire covering sociodemographics, injection risk and protective behaviours, sexual behaviours, HIV knowledge, experiences with drug treatment and harm reduction programmes and social networks. Participants were tested for HIV and hepatitis C by enzyme immunoassay. Data were analysed to identify individual-level, network-level and city-level characteristics significantly associated with HIV prevalence. Factors significant at p≤0.1 were entered into a hierarchical regression model to control for multicollinearity.
Results: A total of 2596 active IDUs were recruited, interviewed and tested for HIV and hepatitis C virus infection. HIV prevalence ranged from 3% (in Voronezh) to 64% (in Yekaterinburg). Although individual-level and network-level variables explain some of the difference in prevalence across the eight cities, the over-riding variable that seems to account for most of the variance is the emergence of commercial, as opposed to homemade, heroin as the predominant form of opioid injected.
Conclusions: The expansion of commercial heroin markets to many Russian cities may have served as a trigger for an expanding HIV epidemic among IDUs in that country.
Corcorran M, Ludwig-Baron N, Cheng D, Lioznov D, Gnatienko N, Patts G AIDS Behav. 2021; 25(8):2533-2541.
PMID: 33730255 PMC: 8222188. DOI: 10.1007/s10461-021-03214-y.
Lunze K, Kiriazova T, Blokhina E, Bushara N, Bridden C, Gnatienko N Glob Public Health. 2020; 16(11):1711-1723.
PMID: 33091311 PMC: 8634803. DOI: 10.1080/17441692.2020.1834599.
Gnatienko N, Lioznov D, Raj A, Blokhina E, Rosen S, Cheng D Addict Sci Clin Pract. 2020; 15(1):1.
PMID: 31931884 PMC: 6958793. DOI: 10.1186/s13722-020-0179-8.
Blokhina E, Krupitsky E, Cheng D, Walley A, Toussova O, Yaroslavtseva T HIV Med. 2019; 20(7):450-455.
PMID: 31034141 PMC: 7255405. DOI: 10.1111/hiv.12741.
Meylakhs P, Friedman S, Meylakhs A, Mateu-Gelabert P, Ompad D, Alieva A AIDS Behav. 2019; 23(12):3350-3365.
PMID: 30989555 PMC: 6788941. DOI: 10.1007/s10461-019-02489-6.